Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25270235 | 0.83 | TDP1 (0.47) | TDP1ALDH1A1SMN1; SMN2GAANPC1 | |
| SCHEMBL31554686 | 0.83 | GAA (0.48) | TDP1ALDH1A1SMN1; SMN2GAANPC1 | |
| SCHEMBL31330879 | 0.83 | TDP1 (0.47) | TDP1ALDH1A1SMN1; SMN2GAANPC1 | |
| SCHEMBL31230971 | 0.83 | TDP1 (0.47) | TDP1ALDH1A1SMN1; SMN2GAANPC1 | |
| SCHEMBL13106351 | 0.80 | TDP1 (0.44) | TDP1ALDH1A1SMN1; SMN2GAANPC1 | |
| SCHEMBL31554591 | 0.78 | TDP1 (0.42) | TDP1ALDH1A1SMN1; SMN2GAANPC1 | |
| SCHEMBL25598078 | 0.76 | CYP1A2 (0.55) | TDP1ALDH1A1SMN1; SMN2GAAMAPT | |
| SCHEMBL31554720 | 0.75 | TDP1 (0.39) | TDP1ALDH1A1SMN1; SMN2GAATSHR | |
| SCHEMBL31554646 | 0.75 | TDP1 (0.39) | TDP1ALDH1A1SMN1; SMN2GAANPC1 | |
| SCHEMBL13106228 | 0.74 | ALDH1A1 (0.49) | TDP1ALDH1A1SMN1; SMN2GAANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7812045-B2 | Antifungal triazole derivatives | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2010-10-12 | — | — | US | disclosed |
| US-20080194661-A1 | Antifungal Triazole Derivatives | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194661-A1 | Antifungal Triazole Derivatives | ERG28, CYP51A1, CYP3A43 | TDP1 2850/4885ALDH1A1 2752/4885SMN1; SMN2 4604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.